San Rafael '71

In May 2026, San Rafael 71’s mix concentrated even further in Flower at 65.92% share with year-over-year sales down 71.17% and month-over-month down 20.97%, while Pre-Roll held 24.33% share with a 63.94% YoY decline and a sharper 43.16% MoM drop. Edible accounted for 6.42% share with sales falling 89.52% YoY and 27.59% MoM, contrasted by Concentrates at 3.07% share posting a 2,541.84% YoY increase and a 2.82% MoM rise. Beverage remained marginal at 0.25% share but jumped 471.09% MoM from a low base; the brand’s overall average price rose 34.61% YoY to $21.40, while the top-category average price in Flower sat at $35.12. The pattern implies a consolidation around higher-priced inhalables where Flower contraction and Pre-Roll retrenchment are only partially offset by nascent growth in Concentrates, leaving total sales still pressured by broad-based YoY declines.

With Flower ranked 68 in Alberta and Pre-Roll sliding faster MoM than Flower by 22.19 percentage points (43.16% vs. 20.97%), San Rafael 71 is ceding lower-price-volume Pre-Roll while leaning into fewer, higher-ticket baskets. The 2,541.84% YoY surge in Concentrates alongside a 471.09% MoM spike in Beverage suggests experimentation at the fringes, yet these categories sum to only 3.32% share, versus 90.26% across Flower and Pre-Roll, and brand sales are down 72.03% YoY with a 86.76% decline over 24 months. This positioning implies the brand is overexposed to contracting core inhalables at higher price points, requiring either re-entry into value tiers or accelerated scaling of Concentrates to counter sustained category headwinds.